TN2013000336A1 - 5s,8s)-3-(4'-chlor-3'-fluoro-4-methylbiphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one (compound a) for therapy. - Google Patents

5s,8s)-3-(4'-chlor-3'-fluoro-4-methylbiphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one (compound a) for therapy.

Info

Publication number: TN2013000336A1
Authority: TN; Tunisia
Prior art keywords: methylbiphenyl; azaspiro; chlor; fluoro; methoxy
Prior art date: 2011-02-06

Application number

TNP2013000336A

Other languages

English (en)

Inventor

Ningshu Liu

Kai Thede

Philip Lienau

Arne Scholz

Christoph-Stephan Hilger

Ulf Bömer

Maher Najjar

Knut Eis

Reiner Fischer

Wahed Ahmed Moradi

Original Assignee

Bayer Ip Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-02-06

Filing date

2013-08-05

Publication date

2015-01-20

2011-02-08 Priority claimed from DE102011011040A external-priority patent/DE102011011040A1/de

2013-08-05 Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh

2015-01-20 Publication of TN2013000336A1 publication Critical patent/TN2013000336A1/fr

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/54—Spiro-condensed
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Indole Compounds (AREA)

TNP2013000336A 2011-02-06 2013-08-05 5s,8s)-3-(4'-chlor-3'-fluoro-4-methylbiphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one (compound a) for therapy. TN2013000336A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
KW1411		2011-02-06
DE102011011040A DE102011011040A1 (de)	2011-02-08	2011-02-08	(5s,8s)-3-(4'-Chlor-3'-fluor-4-methylbiphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-on (Verbindung A) zur Therapie
PCT/EP2012/051895 WO2012104428A1 (fr)	2011-02-06	2012-02-03	Utilisation de (5s,8s)-3-(4'-chloro-3'-fluoro-4-méthylbiphényl-3-yl)-4-hydroxy- 8-méthoxy-1-azaspiro[4.5]décane-3-en-2-one (composé a) à des fins thérapeutiques

Publications (1)

Publication Number	Publication Date
TN2013000336A1 true TN2013000336A1 (en)	2015-01-20

Family

ID=49485835

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TNP2013000336A TN2013000336A1 (en)	2011-02-06	2013-08-05	5s,8s)-3-(4'-chlor-3'-fluoro-4-methylbiphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one (compound a) for therapy.

Country Status (19)

Country	Link
US (1)	US9212140B2 (fr)
EP (1)	EP2670408A1 (fr)
JP (1)	JP2014504624A (fr)
KR (1)	KR20140053844A (fr)
CN (1)	CN103533932A (fr)
AP (1)	AP2013007057A0 (fr)
AR (1)	AR085146A1 (fr)
AU (1)	AU2012213344A1 (fr)
BR (1)	BR112013020015A2 (fr)
CA (1)	CA2826515A1 (fr)
CL (1)	CL2013002247A1 (fr)
EA (1)	EA201391084A1 (fr)
IL (1)	IL227804A0 (fr)
MA (1)	MA34887B1 (fr)
MX (1)	MX2013009065A (fr)
PH (1)	PH12013501638A1 (fr)
TN (1)	TN2013000336A1 (fr)
TW (1)	TW201240659A (fr)
WO (1)	WO2012104428A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP3043800A1 (fr)	2013-09-12	2016-07-20	Pfizer Inc.	Utilisation d'inhibiteurs de l'acétyl-coa carboxylase pour traiter l'acné vulgaire

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1995026954A1 (fr) *	1994-04-05	1995-10-12	Bayer Aktiengesellschaft	1-h-3-aryle-pyrrolidine-2,4-diones a substitution alcoxy-alkyle, utilises comme herbicides et pesticides
DE19813354A1 (de) *	1998-03-26	1999-09-30	Bayer Ag	Arylphenylsubstituierte cyclische Ketoenole
DE10201239A1 (de) *	2002-01-15	2003-07-24	Bayer Cropscience Ag	Fungizide biphenylsubstituierte cyclische Ketoenole
DE102006057037A1 (de) *	2006-12-04	2008-06-05	Bayer Cropscience Ag	cis-Alkoxyspirocyclische biphenylsubstituierte Tetramsäure-Derivate
UY31968A (es) *	2008-07-09	2010-01-29	Sanofi Aventis	Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
DE102010008644A1 (de) *	2010-02-15	2011-08-18	Bayer Schering Pharma Aktiengesellschaft, 13353	Zyklische Ketoenole zur Therapie

2012
- 2012-02-03 PH PH1/2013/501638A patent/PH12013501638A1/en unknown
- 2012-02-03 KR KR1020137023276A patent/KR20140053844A/ko not_active Withdrawn
- 2012-02-03 EP EP12704386.7A patent/EP2670408A1/fr not_active Withdrawn
- 2012-02-03 MA MA36152A patent/MA34887B1/fr unknown
- 2012-02-03 US US13/983,165 patent/US9212140B2/en not_active Expired - Fee Related
- 2012-02-03 MX MX2013009065A patent/MX2013009065A/es not_active Application Discontinuation
- 2012-02-03 EA EA201391084A patent/EA201391084A1/ru unknown
- 2012-02-03 WO PCT/EP2012/051895 patent/WO2012104428A1/fr not_active Ceased
- 2012-02-03 CA CA2826515A patent/CA2826515A1/fr not_active Abandoned
- 2012-02-03 AU AU2012213344A patent/AU2012213344A1/en not_active Abandoned
- 2012-02-03 JP JP2013552225A patent/JP2014504624A/ja active Pending
- 2012-02-03 CN CN201280016212.8A patent/CN103533932A/zh active Pending
- 2012-02-03 BR BR112013020015A patent/BR112013020015A2/pt not_active IP Right Cessation
- 2012-02-03 AP AP2013007057A patent/AP2013007057A0/xx unknown
- 2012-02-06 TW TW101103805A patent/TW201240659A/zh unknown
- 2012-02-06 AR ARP120100376A patent/AR085146A1/es unknown
2013
- 2013-08-05 TN TNP2013000336A patent/TN2013000336A1/fr unknown
- 2013-08-05 IL IL227804A patent/IL227804A0/en unknown
- 2013-08-06 CL CL2013002247A patent/CL2013002247A1/es unknown

Also Published As

Publication number	Publication date
BR112013020015A2 (pt)	2017-03-21
CL2013002247A1 (es)	2014-01-03
CA2826515A1 (fr)	2012-08-09
EA201391084A1 (ru)	2014-02-28
US9212140B2 (en)	2015-12-15
KR20140053844A (ko)	2014-05-08
JP2014504624A (ja)	2014-02-24
PH12013501638A1 (en)	2013-09-16
AR085146A1 (es)	2013-09-11
CN103533932A (zh)	2014-01-22
EP2670408A1 (fr)	2013-12-11
AP2013007057A0 (en)	2013-08-31
MX2013009065A (es)	2013-10-01
AU2012213344A1 (en)	2013-08-22
TW201240659A (en)	2012-10-16
MA34887B1 (fr)	2014-02-01
IL227804A0 (en)	2013-09-30
WO2012104428A1 (fr)	2012-08-09
US20140031407A1 (en)	2014-01-30

Publication	Publication Date	Title
WO2012045090A3 (fr)	2012-07-19	Utilisation thérapeutique d'un agoniste de tlr, et polythérapie
IN2012DN06720A (fr)	2015-10-23
AU2011328009A8 (en)	2013-08-01	Compounds and methods for treating pain
NZ631144A (en)	2016-12-23	Compositions and methods for transmucosal absorption
SG10201808102WA (en)	2018-10-30	Bicyclic heterocycle compounds and their uses in therapy
IN2015DN00376A (fr)	2015-06-12
MX345928B (es)	2017-02-23	Composiciones terapeuticamente activas y metodos de uso de las mismas.
MX2013011908A (es)	2014-03-27	Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank.
ES2397889A1 (es)	2013-03-12	PÉPTIDOS MODULADORES DE PGC-1Alfa.
PH12012502161A1 (en)	2019-07-17	Pharmaceutical formulations comprising pioglitazone and linagliptin
WO2015054619A3 (fr)	2015-06-04	Utilisation d'un inhibiteur de pcsk9 pour traiter l'hyperlipidémie
MX2014010590A (es)	2014-09-18	Terapia de combinacion para trastornos proliferativos.
PH12014500386A1 (en)	2019-10-07	Combination treatment for hepatitis c
MX2010005631A (es)	2010-06-02	Nuevos compuestos de hidrocarburo ciclicos para el tratamiento de enfermedades.
GB201111485D0 (en)	2011-08-17	Drug composition and its use in therapy
IN2015DN00450A (fr)	2015-06-26
EP2582682A4 (fr)	2013-12-04	Procédés pour traiter une affection pulmonaire
WO2012142615A3 (fr)	2013-01-31	Auranofine et analogues d'auranofine utiles pour traiter une maladie proliférative et des troubles prolifératifs
PH12014500250A1 (en)	2014-03-17	Substituted 3-(biphenyl-3-yl)-4 -hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one
WO2013071056A3 (fr)	2013-07-11	Polythérapie médicamenteuse pour le traitement de tumeurs solides
MX360409B (es)	2018-10-30	Terapia de combinacion de dosis fija para la enfermedad de parkinson.
MX356317B (es)	2018-05-23	Tratamiento de síntomas asociados a gastroparesia femenina.
MX348723B (es)	2017-06-27	Combinaciones de solifenacina y estimulantes salivales para el tratamiento de la vejiga hiperactiva.
TW201129361A (en)	2011-09-01	Methods for treating pain
TN2013000336A1 (en)	2015-01-20	5s,8s)-3-(4'-chlor-3'-fluoro-4-methylbiphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one (compound a) for therapy.